Observation on clinical efficacy of serplulimab in non-small cell lung cancer and its influence on T cell function

YANG Xiuyuan; YU Lei

doi:10.3969/j.issn.1674-3806.2025.12.13

Abstract：Objective To observe the clinical efficacy of serplulimab in non-small cell lung cancer(NSCLC)and its influence on T cell function.Methods A total of 162 patients with NSCLC who were admitted to Taizhou People's Hospital from December 2022 to April 2024 were recruited and divided into serplulimab treatment group(58 patients)and conventional chemotherapy group(104 patients)according to the patients'treatment intentions.The conventional chemotherapy group received a platinum-based concurrent chemotherapy regimen,while the serplulimab treatment group received the same chemotherapy regimen as the conventional chemotherapy group plus an additional serplulimab treatment.All the patients were treated continuously for 2 cycles(3 weeks as 1 treatment cycle).The levels of T lymphocyte subsets and tumor markers were compared between the patients in the two groups before and after treatment.The therapeutic effects were evaluated according to Response Evaluation Criteria in Solid Tumors version 1.1(RECIST 1.1).After a one-year follow-up,the progression-free survival and the occurrence of adverse reactions were compared between the two groups.Results After treatment,the levels of serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)and cytokeratin fragment antigen 21-1(CYFRA21-1)in both groups were significantly lower than those before treatment(P＜0.05),but there were no statistically significant differences in the levels of these indicators between the two groups after treatment(P＞0.05).Compared with those in the conventional chemotherapy group,the levels of CD4+and CD4+/CD8+ratio in the serplulimab treatment group were higher after treatment(P＜0.05),and the differences were statistically significant(P＜0.05).The objective response rate and disease control rate of the patients in the serplulimab treatment group were significantly higher than those in the conventional chemotherapy group(58.62%vs 37.50%,χ2=6.709,P=0.010;82.76%vs 60.58%,χ2=8.493,P=0.004).The median progression-free survival in the serplulimab treatment group was 12 months and that in the conventional chemotherapy group was 9 months.The prognosis of progression-free survival in the serplulimab treatment group was significantly better than that in the conventional chemotherapy group(log-rank test:χ2=10.931,P=0.001).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Serplulimab has good clinical therapeutic effects on NSCLC.It can effectively improve T lymphocyte immune function and levels of serum tumor markers in the NSCLC patients,and has clinical promotion value.